Comparison of pioglitazone and metformin efficacy using homeostasis model assessment

Diabetic Medicine

Volumn 21, Issue 2, 2004, Pages 136-141

  Nagasaka, S ^a   Aiso, Y ^b   Yoshizawa, K ^b   Ishibashi, S ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Aiso Clinic   (Japan)

Author keywords

Homeostasis model assessment; Metformin; Pioglitazone

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES CONTROL; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN SENSITIVITY; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 1242292307     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01083.x     Document Type: Article

References (26)

1. Stumvoll M, Nurjahan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New Engl J Med 1995; 333: 550-554.
2. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New Engl J Med 1999; 338: 867-872.
3. Chu NV, Kong APS, Kim DD, Armstrong D, Baxi S, Deutsch R et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002; 25: 542-549.
4. Kelly IE, Han TS, Walsh K, Lean MEJ. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293.
5. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22: 908-912.
6. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23: 1067-1071.
7. Nakamura T, Funahashi T, Yamashita S, Nishida M, Nishida Y, Takahashi M et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diabetes Res Clin Pract 2001; 54: 181-190.
8. Katoh S, Hara S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy - a randomized controlled trial. Metabolism 2001; 50: 414-417.
9. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
10. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 1999; 42: 406-412.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
12. Scheen AJ, Lefebvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22: 1568-1577.
13. Nagasaka S, Iwamoto Y, Ishikawa S, Kuzuya T, Saito T. Efficacy of troglitazone measured by insulin resistance index. Lancet 1997; 350: 184 (Letter).
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
15. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999; 22: 818-822.
16. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
17. Taniguchi A, Nagasaka S, Fukushima M, Sakai M, Nagata I, Doi K et al. Assessment of insulin sensitivity and insulin secretion from the oral glucose tolerance test in nonobese Japanese type 2 diabetic patients. Diabetes Care 2000; 23: 1439-1440 (Letter).
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-2139.
20. Hallsten K, Virtanen KA, Lonnqvist F, Sipila H, Oksanen A, Viljanen T et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51: 3479-3485.
21. Staels B. The clinical significance of PPARα and γ agonism. Br J Diabetes Vasc Dis 2002; 2 (Suppl. 2): S28-S31.
22. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
23. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin. Therapeutic and cellular mechanisms. Drugs 1999; 58: 31-39.
24. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 102: 491-497.
25. Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N. Obesity and type 2 diabetes in Japanese subjects. Lancet 2003; 361: 85 (Letter).
26. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. A 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-1611.